Role for ezrin in breast cancer cell chemotaxis to CCL5

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 965-971

  Li, Juanjuan ^a   Tu, Yi ^a   Wen, Jing ^a   Yao, Feng ^a   Wei, Wen ^a   Sun, Shengrong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Breast cancer; CC chemokine ligand 5; Ezrin; Invasion

Indexed keywords

ACTIN; EZRIN; RANTES; SHORT HAIRPIN RNA;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INVASION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOTAXIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; CHEMOKINE CCL5; CYTOSKELETAL PROTEINS; CYTOSKELETON; FEMALE; FLOW CYTOMETRY; HUMANS; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 77957358826     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000943     Document Type: Article

References (35)

1. Nicolson GL: Paracrine and autocrine growth mechanism in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev 12: 325-343, 1993.
2. Lévesque J-P, Hendy J, Takamatsu Y, et al: Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. Clin Invest 111: 187-196, 2003.
3. Youngs SJ, Ali SA, Taub DD and Rees RC: Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71: 257-266, 1997.
4. Muèller A, Homey B, Soto H, et al: Involve-ment of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
5. John AE, Berlin AA and Lukacs NW: Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation. Eur J Immunol 33: 1677-1685, 2003.
6. Azenshtein E, Luboshits G, Shina S, et al: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62: 1093-1102, 2002.
7. Stormes KA, Lemken CA, Lepre JV, et al: Inhibition of metastasis by inhibition of tumor derived CCL5. Breast Cancer Res Treat 89: 209, 2005.
8. - phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 21: 1113-1121, 2009.
9. Wigler N, Shina S, Kaplan O, et al: Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease. IMAJ 4: 940-943, 2002.
10. Yaal-Hahoshen N, Shina S, Leider-Trejo L, et al: The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12: 4474, 2006.
11. Soria G and Baruch AB: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285, 2008.
12. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz- Mercer B, Chaitchik S, Keydar I and Ben Baruch A: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59: 4681-4687, 1999.
13. Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
14. Robinson SC, Scott KA, Wilson JL, et al: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63: 8360-8365, 2003.
15. Sato N, Funayama N, Nagafuchi A, Yonemura S and Tsukita S: A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J Cell Sci 103: 131-143, 1992.
16. Shaw RJ, Henry M, Solomon F and Jacks T: RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell 9: 403-419, 1998.
17. Takahashi K, Sasaki T, Mammoto A, Hotta I, Takaishi K, Imamura H, Nakano K, Kodama A and Takai Y: Interaction of radixin with Rho small G protein GDP/GTP exchange protein Dbl. Oncogene 16: 3279-3284, 1998.
18. Gautreau A, Poullet P, Louvard D and Arpin M: Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 7300-7305, 1999.
19. Algrain M, Turunen O, Vaheri A, Louvard D and Arpin M: Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol 120: 129-139, 1993.
20. Vaheri A, Carpen O, Heiska L, Helander TS, Jaaskelainen J, Majander-Nordenswan P, Sainio M, Timonen T and Turunen O: The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 9: 659-666, 1997.
21. Curto M and McClatchey AI: Ezrin: a metastatic determinant? Cancer Cell 5: 113-114, 2004.
22. Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med 10: 201-204, 2004.
23. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS and Merlino G: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10: 175-181, 2004.
24. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10: 182-186, 2004.
25. Makitie T, Carpen O, Vaheri A and Kivela T: Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 42: 2442-2449, 2001.
26. Tokunou M, Niki T, Saitoh Y, Imamura H, Sakamoto M and Hirohashi S: Altered expression of the ERM proteins in lung adenocarcinoma. Lab Invest 80: 1643-1650, 2000.
27. Elliott BE, Meens JA, SenGupta SK, Louvard D and Arpin M: The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7: R365-R373, 2005.
28. Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y, Liu P, Song A, Gang C, Han Z, Zhou J, Meng L, Lu Y, Wang S and Ma D: Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 261: 55-63, 2008.
29. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K and Naftolin F: Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 147: 31-38, 1999.
30. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
31. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004.
32. Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I, Schroder JM and Schadendorf D: The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumuor formation in nude mice. Br J Cancer 79: 1025-1031, 1999.
33. Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K, Enblad G and Nilsson G: Expression of CCL5/ RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 107: 197-201, 2003.
34. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez- Mouton C, Jimenez-Baranda S, Garzon A, Lacalle RA, Harshman K, Ruiz A and Martinez A: CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 198: 1381-1389, 2003.
35. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y and Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7: 285-289, 2001.